Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Total Liabilities (2016 - 2025)

Neuroone Medical Technologies (NMTC) has disclosed Total Liabilities for 14 consecutive years, with $2.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities fell 38.87% year-over-year to $2.2 million, compared with a TTM value of $2.2 million through Dec 2025, down 38.87%, and an annual FY2025 reading of $3.7 million, down 18.36% over the prior year.
  • Total Liabilities was $2.2 million for Q4 2025 at Neuroone Medical Technologies, down from $3.7 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $4.5 million in Q3 2024 and bottomed at $952478.0 in Q2 2022.
  • Average Total Liabilities over 5 years is $2.1 million, with a median of $1.8 million recorded in 2023.
  • The sharpest move saw Total Liabilities tumbled 81.0% in 2021, then surged 153.46% in 2024.
  • Year by year, Total Liabilities stood at $1.2 million in 2021, then rose by 20.46% to $1.5 million in 2022, then dropped by 5.66% to $1.4 million in 2023, then soared by 153.46% to $3.6 million in 2024, then plummeted by 38.87% to $2.2 million in 2025.
  • Business Quant data shows Total Liabilities for NMTC at $2.2 million in Q4 2025, $3.7 million in Q3 2025, and $2.6 million in Q2 2025.